The system combines Repligen’s alternating tangential flow (ATF) system with Sartorius’ BioStat reactor allowing an intensified upstream process for biomanufacturers, according to the firms.
With Sartorius’ Biostat stirred-tank reactor (STR) reactor now equipped with Repligen’s hardware and software module, the firms claim intensified seed train and N perfusion implementation will be simpler and more efficient for customers.
Furthermore, the firms claim the joint offering will enable better facility utilization for customers through the creation of a single point of control for 50 L to 2000 L upstream intensification processes.
“The successful pairing of our market-leading XCell ATF intensification control technology with Sartorius’ single-use bioreactors provides end users with a simplified, easy-to-implement perfusion-enabled bioreactor solution for more efficient, higher density cell culture processes,” said Christine Gebski, SVP of Filtration & Chromatography at Repligen.
Mario Becker, head of Product Group Bioreactor Technologies at Sartorius, added: “Ultimately, our goal is to help customers bring more therapeutics to patients faster, and this launch advances our journey along that path to enable continuous manufacturing.”
The joint system will be available to biomanufacturers via Sartorius.